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Summary
Objective Homozygous mutations in the TSH beta subunit
gene (TSHB) result in severe, isolated, central congenital
hypothyroidism (CCH). This entity evades diagnosis in TSH-
based congenital hypothyroidism (CH) screening programmes in
the UK and Ireland. Accordingly, genetic diagnosis, enabling
ascertainment of affected relatives in families, is critical for
prompt diagnosis and treatment of the disorder.
Design, Patients and Measurements Four cases of isolated
TSH deficiency from three unrelated families in the UK and Ire-
land were investigated for mutations or deletions in TSHB.
Haplotype analysis, to investigate a founder effect, was under-
taken in cases with identical mutations (c.373delT).
Results Two siblings in kindred 1 were homozygous for a pre-
viously described TSHB mutation (c.373delT). In kindreds 2 and
3, the affected individuals were compound heterozygous for
TSHB c.373delT and either a 54-kB TSHB deletion (kindred 2,
c.1-4389_417*195delinsCTCA) or a novel TSHB missense muta-
tion (kindred 3, c.2T>C, p.Met1?). Neurodevelopmental retarda-
tion, following delayed diagnosis and treatment, was present in
3 cases. In contrast, the younger sibling in kindred 1 developed
normally following genetic diagnosis and treatment from birth.
Conclusions This study, including the identification of a sec-
ond, novel, TSHB deletion, expands the molecular spectrum of
TSHB defects and suggests that allele loss may be a commoner
basis for TSH deficiency than previously suspected. Delayed
diagnosis and treatment of profound central hypothyroidism in
such cases result in neurodevelopmental retardation. Inclusion
of thyroxine (T4) plus thyroxine-binding globulin (TBG), or free
thyroxine (FT4) in CH screening, together with genetic case
ascertainment enabling earlier therapeutic intervention, could
prevent such adverse sequelae.
(Received 8 April 2016; returned for revision 24 June 2016; finally
revised 24 June 2016; accepted 28 June 2016)
Introduction
Isolated congenital central hypothyroidism is rare (incidence 1 in
65 000),1 with genetic causes comprising mutations in the TSH
beta subunit (TSHB), the immunoglobulin superfamily member 1
(IGSF1) or, less frequently, the TRH receptor (TRHR) genes.2
Central hypothyroidism is associated with either subnormal or
inappropriately normal TSH levels and therefore evades diagnosis
in the UK and Irish TSH-based newborn screening programmes
for congenital hypothyroidism (CH). Unfortunately, patients may
then present later in the neonatal period with overt clinical
hypothyroidism; in TSHB mutation cases, thyroid hormone defi-
ciency is profound, resulting in neurodevelopmental retardation.3
Heterodimeric TSH, secreted by anterior pituitary thyrotroph
cells, comprises a hormone-specific beta subunit (TSHb) and a
common alpha subunit (aGSU) shared with other members of
the glycoprotein hormone family (luteinizing hormone, follicle-
stimulating hormone and chorionic gonadotrophin). The integ-
rity and bioactivity of the heterodimer are maintained by a ‘seat
belt’ structure formed by the b-subunit peptide that is stabilized
by disulphide bridges including the so-called buckle between
amino acids 39 and 125.4
The human TSHb subunit gene is organized into 3 exons:
exon 1 is untranslated, and exons 2 and 3 encode a 138-amino
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acid peptide. The twenty N-terminal amino acids encode a sig-
nal peptide that is cleaved to yield a 118-amino acid mature
protein detectable in serum.4,5 The most frequently described
TSHB mutation is a single-nucleotide deletion (c373delT),
resulting in a cysteine 125 to valine conversion (C125V) and dis-
ruption of the Cys-Cys 39–125 disulphide bridge, with a subse-
quent shift in reading frame and premature stop codon at
position 134.6 Eight additional mutations have been described,
including missense (p.C108Y, p.C105R, p.G49R) and nonsense
or frameshift mutations (p.E32*, p.Q69*, p.F77Sfs*6).3,7–11 Two
splice site mutations (c162G>A, IVS2 + 5 G>A),3,12 and more
recently a homozygous TSHB deletion, have also been
reported.13 All are inherited in an autosomal recessive manner
and are associated with severe central hypothyroidism. (The
nomenclature of mutations in this paper follows the most recent
HGNC guidelines to include the 20-amino acid signal peptide of
TSHb, such that codon numbering may differ from that cited in
the previously published articles).
We report three kindreds from the UK or Ireland in which
four cases exhibit isolated central hypothyroidism secondary to
TSHB mutations. In kindred 1, two siblings (P1a and P1b) are
homozygous for the previously described c.373delT mutation. In
kindred 2, the affected child (P2) is compound heterozygous for
c.373delT together with a maternally derived 54-kb deletion
involving TSHB alone (c.1-4389_417*195delinsCTCA). In kin-
dred 3, the proband (P3) is compound heterozygous for
c.373delT and a novel missense mutation (c.2T>C, p.Met1?),
disrupting the methionine residue from which translation is ini-
tiated. We describe these TSHB defects and associated clinical
phenotypes in the context of the wider literature.
Patients and methods
Clinical phenotype, auxological parameters and biochemistry for
each case are summarized in Table 1.
Patients 1a and 1b (P1a and P1b)
P1a is the second son of healthy, nonconsanguineous Cau-
casian (UK) parents. Although his TSH on neonatal screening
was reported normal, he presented aged 3 weeks with a lower
respiratory tract infection and was noted to have clinical fea-
tures of hypothyroidism, including somnolence, constipation
and dry skin. Thyroid function tests were consistent with sev-
ere central hypothyroidism (total T4 < 10 nmol/l, normal range
50–160; TSH 01 mU/l, NR 01–5), with no TSH response to
TRH stimulation. Subsequent dynamic testing, showing pre-
served corticotroph, somatotroph and gonadotroph function,
excluded combined pituitary hormone deficiency (data not
shown), and his basal prolactin level was 554 mU/l (NR <700).
Levothyroxine treatment was commenced at the age of 5 weeks
and 2 days, despite good compliance development was delayed.
Formal assessment of age 2 years revealed significantly
impaired hearing and speech. At age 7 years, growth is normal,
and he is in mainstream education, but requires additional
support.
P1b, the younger brother of P1a, underwent screening for
central hypothyroidism at birth following this diagnosis in his
older sibling. Thyroid function was consistent with TSH defi-
ciency (cord blood fT4 65 pmol/l, NR 10–24; TSH <005 mU/l,
NR 03–4). Levothyroxine was commenced at age 1 week, and
Table 1. Clinical phenotype, auxological and biochemical parameters for each case harbouring TSHB mutations
P1a P1b P2 P3
Neonatal screening TSH (mU/l) ‘Normal’ ‘Normal’ <1 0
Gestational length (weeks) 42 42 40 39
Birth weight (kg) 371 414 318 28
At diagnosis
Age (weeks) 5 Birth 8 14
Body length (cm) and centile 562 (25th) NA 51 (<3rd) <3rd
Body weight (kg) and centile 560 (75th) 414 (75th) 352 (<3rd) NA(3rd)
TSH (mU/l) 01(01–50) <005(03–40) 278 (04–40) 045 (04–35)
fT4 (pmol/l) <10(50–160)* 65(10–24) <389(10–25) <51 (138–225)
Peak TSH response to TRH 009 NA 321 NA
MRI pituitary Normal NA Normal Normal
Extrathyroidal abnormalities
Neurodevelopment Mild motor and sensory
processing deficits, extra
support at school
Normal Mild motor delay Horizontal pendular nystagmus,
bilateral sensorineural hearing
loss developmental delay
(motor, language), Autism/Asperger
spectrum
Attends special school
Haematological Macrocytic anaemia Macrocytic anaemia
*In P1a, the T4 value refers to total T4 (nmol/l). In three cases, the absolute T4 value could not be quantified because it was significantly below the
lower limit of the normal reference range (P1a, 50–160 nmol/l, Ciba Corning ACS 180) or reportable range quoted by the assay manufacturer (P2 39p-
mol/l, Siemens Immulite 2500 SMS, P3 51pmol/l, Abbott AxSym Immunoassay).
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he subsequently grew and developed normally. Both parents are
clinically and biochemically euthyroid.
Patient 2 (P2)
P2 is the daughter of healthy, nonconsanguineous Caucasian
(Irish) parents. Her TSH in neonatal screening was normal. She
presented aged 8 weeks with prolonged jaundice, poor weight gain
and feeding since birth, somnolence and constipation. She was
clinically hypothyroid, with cool peripheries, hypotonia, an
umbilical hernia, cutis marmorata, coarse facial features and
macroglossia. Severe biochemical central hypothyroidism was
confirmed (fT4 < 389 pmol/l, NR 10–25; TSH 278 mU/l, NR
04–40). In a TRH stimulation test, the TSH response was absent,
but prolactin levels rose (basal prolactin 723 mU/l, 20 min pro-
lactin 1064 mU/l), suggesting a defect downstream of the TRH
receptor. Dynamic evaluation of corticotroph and somatotroph
function was normal. Following commencement of levothyroxine
aged 8 weeks, her growth was normal. Despite good compliance
with treatment, she exhibits mild motor delay at age 7 years. Both
parents are clinically and biochemically euthyroid.
Patient 3 (P3)
P3 is the only daughter of healthy, nonconsanguineous Cau-
casian (UK) parents. Her TSH in neonatal screening was
reported as normal. She presented aged 35 months with feeding
difficulties, somnolence, constipation and severe growth retarda-
tion. She was clinically hypothyroid with a small umbilical her-
nia and depressed nasal bridge. Thyroid biochemistry confirmed
profound central hypothyroidism (fT4 < 51 pmol/l, NR 138–
225; TSH 045 mU/l, NR 04–35). Subsequent evaluation of
pituitary–adrenal, gonadotrophins and basal serum prolactin was
normal. Although her growth response to levothyroxine treat-
ment was excellent, she has multiple neurodevelopmental deficits
including bilateral sensorineural deafness and nystagmus without
optic nerve hypoplasia. Motor and language development was
significantly delayed; at the age of 10 years, she is on the autis-
tic/Asperger’s spectrum. She has a statement of Special Educa-
tional Needs and is unable to attend mainstream school. Her
mother is clinically and biochemically euthyroid; her father is
not available for evaluation.
Methods
All investigations were part of an ethically approved protocol
and/or clinically indicated, being undertaken with the consent
from patients and/or next of kin.
Sanger sequencing of the TSHB subunit gene
Genomic DNA was extracted from peripheral blood leucocytes
using the standard techniques. All three TSHB subunit gene
exons and exon/intron boundaries were amplified by PCR using
specific primers: 5’-TCCAGGTAAAGATATTGTGAGCT-3’ and
5’-TTACAGCCTGTTGAAGCAAATT-3’ (exon 1), 5’-CCTAGA
TTTCTGAGTTAGCCCCT-3’ and 5’-TGCGTATCCATTGTGCT
GAG-3’ (exon 2) and 5’-TGTTTCCTAAAGTCCTGTCACA-3’
and 5’-ACCTTCAACTGAGCCCAAAAG-3’ (exon 3). To charac-
terize the chromosomal deletion around TSHB in P3, the
homozygous region delineated by SNP markers rs7523360 and
rs1998008 was amplified by long-range PCR using the primers
5’-AACACACATCCAACATTCTTCCA-3’ and 5’-AAATCCCGC
AGTAATTCTTTGCT-3’.
PCR products were sequenced using the BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
USA) and 3730 DNA Analyzer (Applied Biosystems). The TSHB
variants listed in this study are described using the systematic
nomenclature approved by the Human Genome Variation Soci-
ety (HGVS; varnomen.hgvs.org). Nucleotide numbering starts
from the A (+1) of the translation initiation codon (ATG) of
the NCBI reference sequence NM_000549.4 and includes the 20-
amino acid signal peptide. Amino acid residues are numbered
according to the NCBI reference sequence NP_000540.2.
Haplotype analysis
To determine chromosome 1 haplotypes, individuals were geno-
typed for single-nucleotide polymorphisms with MAF >038
from seven linkage disequilibrium blocks selected using Haplo-
view (The Broad Institute, USA) and spanning 225 kb 5’ and
205 kb 3’ of the TSHB locus (Figure 3, primers available on
request).
In silico tools
In silico analysis of the novel missense variant (c.2T>C) was per-
formed using Alamut as an interface (Interactive Biosoftware,
Rouen, France) and the SignalP V4.1 signal peptide prediction
package (www.cbs.dtu.dk/services/SignalP) to determine whether
translation from Met-7 would alter the probability of the protein
sequence acting as a signal peptide.14
TaqMan quantitative real-time PCR (qPCR) analysis of
TSHB gene copy number
The following intra-exonic primer/probe sets were used to quan-
tify genomic TSHB copy number and genomic THRA in P3, her
parents, and 10 unrelated, euthyroid controls. TSHB: primer/
probe set Hs02759015_s1 (ABI Life Technologies); THRA: for-
ward 5’-TTCGAGCACTACGTCAACCA-3’; reverse 5’-CCCGAT
CATGCGGAGGTCAG-3’; probe 5’-FAM CACAACATTCCGCA
CTTCTG-TAMRA-3’ using qPCR as previously described.15 The
comparative Ct method was used to quantify genomic TSHB
normalized to genomic THRA.
Results
TSHB analysis using Sanger sequencing
P1a and P1b were homozygous for a single-nucleotide deletion
in TSHB, c.373delT, p.C125Vfs*10 (c.313delT, p.C105Vfs114X,
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legacy numbering), described previously, with both euthyroid
parents being heterozygous. Despite paternal heterozygosity for
this mutation, but wild-type maternal TSHB sequence (Fig. 1a),
P2 was apparently homozygous for the same mutation
(p.C125Vfs*10). This suggested uniparental inheritance of the
mutation, due to either paternal, uniparental disomy or a mater-
nal deletion involving the TSHB locus. P3 was heterozygous for
the p.C125Vfs*10 mutation and a novel missense mutation
(c.2T>C, p.Met1?), disrupting the start site for translation at the
beginning of the signal peptide of TSHb. As the maternal TSHB
locus only showed heterozygosity for the c.2T>C, p.Met1?
change, these mutations were assumed to be compound
heterozygous, occurring on separate alleles.
Investigation to define the TSHB deletion in P2
TaqMan qPCR was used to quantify TSHB copy number in P2,
her parents, and ten unrelated, euthyroid controls. The results,
showing a fifty per cent decrease in amplified signal from the
TSHB locus in P2 and her mother, were consistent with a
maternal, heterozygous TSHB deletion (Fig. 1b).
P2 and both parents were genotyped for single-nucleotide
polymorphisms around the TSHB locus. This analysis delineated
a 211-Kb region with loss of heterozygosity at 1p132, with
heterozygous SNPs confirming obligate biparental inheritance at
the boundaries of this interval. An informative SNP (rs1321108),
44 kb proximal to TSHB, confirmed uniparental (paternal)
Fig. 1 (a) Apparent uniparental inheritance of the TSHB c.373delT mutation in P2: Chromatograms obtained from TSHB sequencing in P2 and
parents; P2 is homozygous for a single-nucleotide deletion at position 373 (c.373delT), and her father is heterozygous for the mutation as predicted.
Surprisingly, the maternal sequence is apparently wild type. (b) Decreased genomic TSHB in P2 and her mother are consistent with a maternally
inherited TSHB deletion: TaqMan qPCR was used to quantify genomic TSHB normalized to genomic THRA levels and expressed as a percentage of the
mean for 10 euthyroid controls; levels in P2 and her mother are approximately fifty per cent of those in her father and controls, consistent with a
heterozygous maternal genomic deletion at the TSHB locus. P-values were computed using a 2-tailed Student’s t-test. (c) Single-nucleotide
polymorphism (SNP) genotyping around the TSHB locus defines the deleted region in P2: Schematic summarizing SNP genotyping around the TSHB
locus. Light grey: SNPs with obligate uniparental inheritance; dark grey: heterozygous SNPs defining the boundaries of obligate diparental inheritance.
Single bases in P2 define the region of loss of heterozygosity. (d) Maternally inherited deletion–insertion in P2: Schematic of the TSHB locus and
sequencing chromatogram defining the maternal deletion–insertion for which P2 was compound heterozygous.
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inheritance at this site (A/A), as no maternal allele (G/G) was
inherited (Fig. 1c). Subsequent Sanger sequencing of the region,
using a long-range PCR, confirmed a 54-kb maternal deletion
involving only the TSHB locus, together with a 4-bp insertion
(c.1-4389_417*195delinsCTCA) (Fig. 1d).
In silico prediction of the deleterious consequences of
the c.2T>C mutation in P3
P3 exhibits a novel missense mutation (c.2T>C), in which a
methionine codon, from which translation is initiated, is
replaced by a threonine. This mutation was absent from the
published normal genome data sets (dBSNP, 1000 Genomes,
Exome Aggregation Consortium (ExAC), Cambridge, MA (URL:
http://exac.broadinstitute.org), April 8th, 2016). Alamut predic-
tive software suggests that this substitution will adversely affect
translation of the TSHb polypeptide.
In higher eukaryotes, efficient initiation of translation is gov-
erned by the nucleotide sequence surrounding the ATG start
codon (GCCGCCA/GCCAUGG, initiator codon underlined),
with a purine (usually A) at position -3 (5’) and guanine at
position +4 (3’), relative to the adenine (A) of the initiator
codon (Fig. 2a).16 Thus, although there is an alternative, in-
frame, ATG start codon at Met-7, the nucleotide sequence sur-
rounding Met-7 (CTCTTTCTGATGT) lacks both a purine at
position -3 (C, bold) and a guanine at position +4 (T, bold),
suggesting that efficient translation from this alternative site is
unlikely. Additionally, as the first 20 amino acids of TSHb form
a signal peptide, even if limited synthesis from Met-7 of TSHb
occurs, the resulting N-terminally deleted TSHb polypeptide
would lack hydrophobic residues within its signal sequence that
may be critical for correct protein translocation (Fig 2a).17
SignalP 4.1 software14 also predicts that if translation occurred
from Met-7, the ability to appropriately cleave signal peptide
from TSHb polypeptide would be lost (Fig. 2b). Taken together,
these features suggest that the c.2T>C TSHB mutation is likely
to result in significantly impaired biosynthesis of functional
TSHb polypeptide.
Haplotype analysis around the TSHB c.373delT mutation
Genotyping for single-nucleotide polymorphisms around TSHB
indicates that all four cases share an extended haplotype for the
c.373delT mutation, suggesting common ancestry (Fig. 3a,b).
Intriguingly, all of the UK cases may be of Irish descent; P3,
with presumed paternal inheritance of c.373delT, confirms
paternal Irish descent; P1a and P1b also acknowledge paternal
Irish ancestry.
Discussion
This report represents first documentation of three different
TSHB mutations in patients from the UK and Ireland exhibiting
characteristic clinical features, although two American cases of
Scottish–Irish ancestry have been described.18 Neurodevelop-
mental retardation is a consistent feature in TSHB mutation
cases, often attributed to delayed diagnosis and initiation of
treatment, as these individuals are not detected in TSH-based,
CH screening programmes.3 Thus, in our patients, severity of
neurodevelopmental impairment correlates with the age of thy-
roxine commencement: in P3, who was diagnosed aged
35 months, neurodevelopmental retardation is most marked,
and she requires special schooling; despite initiation of treatment
aged 6 or 8 weeks, respectively, P1a and P2 both exhibit mild
neurodevelopmental impairment; in P1b, who was screened,
diagnosed and treated at birth, neurological development was
normal.
P3 exhibits a constellation of neurological deficits, much of
which can be explained by early postnatal hypothyroxinaemia.
Sensorineural hearing loss has been described in association with
both primary and secondary hypothyroidism 3,19,20 and reflects
the essential role of thyroid hormone in the auditory develop-
ment for maturation and innervation of cochlear hair cells, and
development of central auditory pathways.21,22 Additionally, nys-
tagmus has been reported in the context of primary congenital
hypothyroidism 23,24 and, given the importance of thyroid hor-
mone in postnatal cerebellar granule cell development, may indi-
cate defective maturation of cortico-pontine-cerebellar
pathways.25 The complex neurodevelopmental abnormalities in
P3 include autistic spectrum disorder, which, being reportedly
associated with hypothyroxinaemia in utero rather than postna-
tally,26 might not be aetiologically linked to her congenital TSH
deficiency, although a role for early postnatal hypothyroxinaemia
may be plausible. Given the crucial postnatal role of thyroxine
in the development of visuospatial, language and sensorimotor
skills, central hypothyroidism is likely to have contributed to her
neurodevelopmental delay.25
Our cases exhibit three different genetic aetiologies including
one novel missense TSHB mutation (P3, c.2T>C, p.Met1?).
Mutation of a normal mammalian ATG start codon to ACG
usually results in markedly diminished protein translation 27 and
thus would be expected to cause significantly reduced synthesis
of full-length TSHb polypeptide from the mutant allele. Another
in-frame ATG codon, six residues downstream (Met-7), is sur-
rounded by an unfavourable nucleotide context for translational
initiation, lacking both a purine at position -3 and a guanine at
position +4.16 Even if limited TSHb synthesis from Met-7
occurred, this polypeptide would likely lack a recognizable signal
sequence, compromising TSHb processing and secretion.17 Con-
sistent with such in silico predictions, in vivo data from P3
strongly suggest that negligible bioactive TSH is synthesized
from the c.2T>C allele, as profound hypothyroidism (unde-
tectable fT4) is associated with barely measurable serum levels
(045 mU/l) of intact TSH. Some of this TSH immunoreactivity
may reflect translation of TSHb from the residual c.373delT
TSHB mutant allele, which is known to mediate the limited syn-
thesis of biologically inactive TSH that retains immunoreactivity
in some assays.19
P2 is the first recorded patient in whom a heterozygous dele-
tion (54 kb, c.1-4389_417*195delinsCTCA), encompassing
TSHB alone, has been mapped precisely. Biallelic TSHB deletions
were recently described in a Turkish patient.13 Intriguingly, one
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of the original Brazilian cases with a c.373delT TSHB mutation
exhibited apparent uniparental inheritance; compound heterozy-
gosity of the c.373delT mutation with a TSHB deletion would
also be a plausible alternative explanation in this patient.6 P2
harbours a heterozygous TSHB deletion together with a monoal-
lelic c.373delT mutation, suggesting that TSHB deletions may be
a more common cause of isolated TSH deficiency than previ-
ously thought.
Worldwide, c.373delT is the commonest TSHB mutation
reported, occurring in the unrelated cases from Western Europe,
South America and the USA.28–31 Accordingly, it is unsurprising
that all of our cases harbour c.373delT TSHB either mono- or
biallelically. Previous functional studies have shown that it is the
cysteine to valine amino acid change at codon125, rather than
subsequent deletion of 13 carboxyterminal residues of TSHb,
which impairs the function of mutant TSH.6 This amino acid
substitution disrupts a disulphide bond between C125 and C39
that forms the ‘buckle’ of the TSHb ‘seat belt’ which surrounds
the alpha subunit. Although the c.373delT mutation disrupts the
functional integrity of TSH, alpha and mutant TSHb subunits
can still heterodimerize, forming biologically inactive TSH that
retains immunoreactivity in some immunoassays.19 Consistent
with this observation, the IMMULITE 2000 third-generation
immunoassay (Siemens) detects TSH in P2, albeit at inappropri-
ately low levels. Although the c.373delT nucleotide change
occurs at a mutation hot spot in TSHB, the gene defect is pre-
sent as a founder mutation in some populations.32 Thus, analy-
sis of our UK and Irish cases showed that the mutation also
occured on a common (probably Irish) haplotype background
in these families, supporting the notion of a founder effect.
Fig. 2 (a) Schematic summarizing the deleterious c. 2T>C and c.373delT mutations in P3: Sequencing chromatograms are aligned with a schematic of
the TSHB gene to show the position of the compound heterozygous mutations. The amino acid sequence of the TSHB signal peptide contains a
putative hydrophobic core (underlined) and cleavage site (double vertical line). Translation from Met-7 due to the c.2T>C mutation would result in
loss of the N-terminal portion of the peptide and hydrophobic residues, with the resultant amino acid sequence, highlighted in grey. The cDNA
nucleotide sequence around Met-1 and Met-7 is shown beneath, with the bases at positions -3 and +4 in bold type, defining favourable (Met-1) and
unfavourable (Met-7) Kozak sequences for translation initiation. (b) Translation from Met-7 is likely to abrogate the TSHB signal peptide: Signal P 4.0
analysis output for wild-type TSHB, and TSHB lacking the first 6 amino acids (i.e. the putative peptide generated if translation occurs from Met-7).
The presence of a signal peptide is predicted by scoring every residue (‘S-score’) for the stretch of amino acids analysed. The predicted score for the
signal peptidase cleavage site is indicated by the C-score. Y-score is a composite score for C- and S-scores, to improve cleavage site prediction. The
D-score (discrimination score) is a weighted average of the mean S and the max. Y scores and is used to discriminate signal peptides from nonsignal
peptides, with a value of >045 taken to predict a signal peptide (www.cbs.dtu.dk/services/SignalP-4.0/output.php). Wild-type TSHB (upper panel) is
strongly predicted to contain a cleavable signal peptide within residues 1–20 (C-score 062, Y-score 076, S-score 097, D-score 0853), whereas this
prediction becomes much weaker when Met-7 is used as the translational start site (lower panel), and no clear cleavage site is denoted (C-score 013,
Y-score 024, S-score 052, D-score 0334).
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Screening for congenital central hypothyroidism (CCH) can
be achieved by inclusion of thyroxine (T4) plus thyroxine-bind-
ing globulin (TBG), in the CH screening programme, as in the
Netherlands or fT4 as in Japan. Combined T4/TSH/TBG evalua-
tion in Dutch neonates enables diagnosis of permanent central
CH with an incidence of 1:21 000 newborns.33 The incidence in
Japan has been found to be much lower (1:160 000); however,
although ethnic differences could be contributing, subsequent
studies suggest this may reflect a less sensitive Japanese screening
approach.34,35
The benefits of including T4 measurement in CH screening
continue to be debated with arguments against citing the relative
rarity of congenital central hypothyroidism, with the presump-
tion that it is usually mild and unlikely to be associated with
adverse neurological sequelae. However, screening for CCH
would enable prompt diagnosis and treatment of affected cases,
improving neurodevelopmental outcomes particularly in severe
cases due to TSHB mutations. Moreover, Zwaveling-Soonawala
et al. recently demonstrated that more than 50% of children
diagnosed with CCH in the Netherlands exhibit moderate or
severe hypothyroidism, rather than mild thyroid hormone defi-
cits, thus emphasizing that the potential neurological sequelae of
delayed diagnosis should not be underestimated (Zwaveling-
Soonawala et al. 2015).36 As combined pituitary hormone defi-
ciencies occur in 75 per cent of CCH cases, early diagnosis of
central hypothyroidism would also facilitate the prompt detec-
tion of pituitary–adrenal and growth hormone deficiencies,
potentially preventing their life-threatening consequences.2
Fig. 3 (a) The c.373delT mutation occurs on a common haplotype in all 3 kindreds: Table showing the chromosomal location of genotyped SNPs, and
the genotype of probands and parents. The maternal alleles inherited by the probands are shown in grey italics. P: proband; M: mother; F: father; cells
with grey fill: inheritance unclear. (b) Schematic showing the chromosomal location of genotyped SNPs, within seven blocks 1–7 that are in tight
linkage disequilibrium and their position relative to TSHB and neighbouring SYCP1 and TSPAN2 genes. The location of the c.373delT mutation is
denoted by a star.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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We report the first cases from the UK and Ireland harbouring
TSHB mutations, whose genetic aetiologies include a novel mis-
sense mutation, a compound heterozygous TSHB deletion and a
known frameshift mutation. As well as expanding the known
repertoire of TSHB mutations, our observations suggest that
TSHB deletions may be more common than previously thought
and show that c.373delT TSHB mutation is the most common
genetic defect in cases of central hypothyroidism in the UK and
Ireland. Concordant with other recorded cases, our patients with
isolated TSH deficiency exhibit neurodevelopmental delay when
overt hypothyroidism is diagnosed and treated later postnatally.
As measurement of T4 is not included in UK or Ireland CH
screening programmes, genetic ascertainment in families with
isolated TSH deficiency will be particularly important, enabling
prompt diagnosis of affected children and early treatment to
prevent the adverse neurodevelopmental outcome.
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